-+ 0.00%
-+ 0.00%
-+ 0.00%

Expedition Therapeutics closes oversubscribed $115 million Series B led by General Atlantic, Forbion joins round

PUBT·08/05/2026 12:09:31
Listen to the news
Expedition Therapeutics closes oversubscribed $115 million Series B led by General Atlantic, Forbion joins round
  • Expedition Therapeutics closed an oversubscribed USD 115 million Series B financing that included Forbion Capital Partners Management Services BV.
  • San Francisco-based Expedition develops oral small-molecule therapies for inflammatory, respiratory diseases; lead asset EXPD-101 targets DPP1 in COPD.
  • General Atlantic led the round; RA Capital, Vivo Capital participated alongside existing investors.
  • Proceeds earmarked to advance EXPD-101 through Phase 2 development, expand the pipeline, strengthen research discovery.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forbion Capital Partners Management Services BV published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.